Calidar Launches First Patient Study of 4D Mammography, Aiming to Transform Breast Cancer Diagnosis

Calidar, Inc., a precision diagnostic imaging start-up, has announced the successful imaging of the first patient using its new 4D Mammography system. The breakthrough technology combines X-ray diffraction with artificial intelligence to detect disease at the molecular level, offering a potential leap forward in diagnostic accuracy.

This marks the first known in-human measurement of X-ray diffraction spectra, a milestone the company says could reshape medical imaging.

Breast cancer remains difficult to detect noninvasively with precision. In the U.S., about 1.5 million breast biopsies are performed annually, yet up to 80% ultimately reveal benign results. These unnecessary biopsies cost the healthcare system more than $6 billion each year, while inconclusive imaging delays treatment for an estimated 50,000 breast cancer patients annually.

The burden also falls heavily on clinicians, with radiologist workloads nearly doubling and pathologist caseloads rising more than 40% in the past decade.

Calidar’s 4D Mammography system aims to reduce such challenges by measuring how X-rays scatter at the molecular level through a process called X-ray diffraction. Unlike traditional mammography, which shows only shape and density, this approach reveals the unique molecular “fingerprints” of tissue composition. In previous lab studies, the technology distinguished between benign and cancerous samples with four times the precision of conventional imaging.

“This is more than a study milestone — this is the start of a new era of medical imaging,” said Dr. Stefan Stryker, CEO of Calidar. “X-ray diffraction has driven some of science’s greatest discoveries, from the structure of DNA to planetary exploration. Now, we are bringing its power into the clinic to look inside the human body in a completely new way.”

The current clinical study, conducted in partnership with Baptist Health Hardin in Elizabethtown, Ky., will evaluate the system’s ability to distinguish between healthy and cancerous breast tissue in patients and compare its performance with existing mammography tools.

“We are excited to collaborate on this next-generation research and contribute to technology that could meaningfully enhance our ability to diagnose breast cancer,” said Dr. Craig Kamen, principal investigator of the study.

While the system is currently investigational and not yet FDA-approved, Calidar plans additional studies that will expand its use into breast cancer screening. The goal is to enable earlier detection, reduce unnecessary biopsies, and improve outcomes for patients worldwide.